Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Eagle Pharmaceuticals Inc (EM) EGRX

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell... see more

Current News (EXPM:EGRX)

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

GlobeNewswire January 14, 2026

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

GlobeNewswire October 30, 2025

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

GlobeNewswire October 21, 2025

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

GlobeNewswire October 15, 2025

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

GlobeNewswire October 6, 2025

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

GlobeNewswire September 17, 2025

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

GlobeNewswire August 28, 2025

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

GlobeNewswire August 18, 2025

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

GlobeNewswire March 31, 2025
View More News ››

Opinion & Analysis (EXPM:EGRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:EGRX)

RE:BNN

Eagle Pharmaceuticals Fiscal Q4 Loss Widens More Than Expected Despite Revenue Beat as Expenses Climb,Dec 2014  doesn't sound...
picassolover - January 6, 2015

BNN

Stock made a BNN guests buy list today
HighteawithIntrepid - January 6, 2015
View more Bullboard ››

Walker Lane Resources Ltd.

Walker Lane Resources Ltd.

Walker Lane Resources Ltd. engages in the acquisition and exploration of mineral properties in Canada. The company explores ...
View More »

Podcasts